Accession Number: | 0001209191-20-005129 |
Date: | 2020-01-24 |
Issuer: | IRONWOOD PHARMACEUTICALS INC (IRWD) |
Original Submission Date: |
MCCOURT THOMAS A
C/O IRONWOOD PHARMACEUTICALS, INC.
100 SUMMER STREET, SUITE 2300
BOSTON, MA 02110
Title of Security | Transaction Date | 2a. Deemed Execution Date | Transaction Code | Shares | Acquired or Disposed | Price per share | 5. Amount of Securities Beneficially Owned Following Reported Transaction | 6. Ownership Form Direct or Indirect | Nature of Indirect Ownership |
---|---|---|---|---|---|---|---|---|---|
CLASS A COMMON STOCK | 2020-01-24 | M | 20,000 | a | $10.02 | 245,239 | direct | ||
CLASS A COMMON STOCK | 2020-01-24 | S | 20,000 | d | $12.71 | 225,239 | direct |
Title of Derivative Security | Conversion or Exercise Price of Derivative Security | Transaction Date | Deemed Execution Date | Transaction Code | Number of Derivative Securities Acquired (A) or Disposed of (D) | Date Exercisable | Expiration Date | Title and Amount of Securities Underlying Derivative Security | Price of Derivative Security | Number of derivative Securities Beneficially Owned Following Reported Transaction(s) | Ownership Form: Direct (D) or Indirect (I) | Nature of Indirect Beneficial Ownership |
---|---|---|---|---|---|---|---|---|---|---|---|---|
EMPLOYEE STOCK OPTION (RIGHT TO BUY) | 10.02 | 2020-01-24 | deemed execution date | M | 20,000 (d) | 2020-02-02 | class a common stock 20,000 | $10.02 | 0 | direct |
ID | footnote |
---|---|
f1 | the reporting person acquired 280 shares of class a common stock under the issuer's employee stock purchase plan on december 31, 2019. |
f2 | this sale was effected pursuant to a rule 10b5-1 trading plan adopted by the reporting person. |
f3 | the price reported is a weighted average price. these shares were sold in multiple transactions at prices ranging from $12.33 to $12.98, inclusive. the reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the securities and exchange commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. |
f4 | this option, granted as an annual performance award, is presently exercisable in full. |